Trial reportBMC anesthesiology2026
Perineural injection or intravenous infusion of dexmedetomidine in ultrasound-guided erector spinae plane block combined with serratus anterior plane block for analgesia after thoracoscopic surgery : a randomized controlled study.
Trial report in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThis research aimed to evaluate the analgesic effect of perineural injection or intravenous infusion of dexmedetomidine in ultrasound-guided erector spinae plane block (ESPB) combined with serratus anterior plane block (SAPB) for patients undergoing thoracoscopic surgery.
methodsIn this prospective, double-blind, randomized controlled trial, seventy-five patients scheduled for thoracoscopic surgery were randomly divided into the control group (group R: 40 ml of 0.375% ropivacaine for ESPB combined with SAPB and 40 ml of 0.9% NaCl for intravenous infusion), the intravenous infusion of dexmedetomidine group (group RDiv: 40 ml of 0.375% ropivacaine for ESPB combined with SAPB and 40 ml of 0.9% NaCl containing 1 µg/kg dexmedetomidine for intravenous infusion), and the perineural injection of dexmedetomidine group (group RD: 40 ml of 0.375% ropivacaine containing 1 µg/kg dexmedetomidine for ESPB combined with SAPB and 40 ml of 0.9% NaCl for intravenous infusion). The primary outcome was the duration of effective analgesia, defined as the time from the onset of nerve blocks to the first demand for patient-controlled analgesia. Secondary outcomes included postoperative opioid consumption, rescue analgesia, numeric rating scale (NRS) scores, adverse effects and quality of recovery.
resultsCompared with group R and group RDiv, the duration of effective analgesia in group RD was significantly prolonged (1313.8 ± 372.8 vs. 844.5 ± 285.2 vs. 943.0 ± 417.2 min, P < 0.05), opioid consumption and the number of patients who required rescue analgesia were significantly reduced (P < 0.05), and NRS scores at rest and on movement at 24, 36 and 48 h were all significantly reduced (P < 0.05). Group RD exhibited a reduced incidence of postoperative nausea and vomiting (P < 0.05), along with improved quality of recovery-15 score at 24 h postoperatively (P < 0.05).
conclusionsPerineural injection of dexmedetomidine in ultrasound-guided erector spinae plane block combined with serratus anterior plane block could still significantly prolong the duration of effective analgesia after thoracoscopic surgery, reduce opioid consumption, and improve the occurrence of adverse effects, thereby improving early-term recovery. However, the same clear benefits were not observed with intravenous dexmedetomidine.
trial registrationThe study was registered at Chinese Clinical Trial Registry (https//www.chictr.org.cn) with the number ChiCTR2400088052 on 08/09/2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.